Dr. Valeria Fumagalli is a biotechnologist, and obtained her PhD in molecular medicine at the Vita-Salute San Raffaele University, Milan (IT) in 2020. She is currently a postdoctoral fellow at the Iannacone Lab at the Vita-Salute San Raffaele University (AIRC Fellowship for Italy). She is interested in studying the complex dynamics of host-virus interactions with a particular focus on the function of immune response and seeks to dissect the role of innate lymphoid cells and B cells in mouse models of HBV pathogenesis. Recently, Dr. Fumagalli published two findings that have clinical implications. First, hepatic group 1 innate lymphoid cells (ILCs) might limit the therapeutic efficacy of IL-2 based treatments. Second, contrary to a widely held belief, anti-HBV therapy alone is unlike to increase HBV-specific CD8+ T cell responses. Finally, during the last two years, she has played a leading role in establishing novel mouse models of SARS-CoV-2 infection to study pathogenesis and to test vaccines and antivirals.